AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

The Safety and Performence of ShockPulse-10 in Patients with Coronary Artery Calcification

RecruitingNAAges 18 Years - anyAllKeya Medical
💬

In plain words

What the trial is, and whether it could suit you

This study is an exploratory, multicenter, single-group clinical trial aimed to evaluate the clinical outcomes of using ShockPulse-10 in the treatment of coronary artery calcification .

Sign in to get the eligibility rules as simple questions to take to your doctor.

📋 Eligibility rules (as published)
Key Inclusion Criteria: 1. Patient is ≥ 18 years of age; 2. Patients with significant coronary artery disease (including stable or unstable angina and asymptomatic myocardial ischemia) who are suitable for PCI treatment; 3. A single newly developed stenosis of the target vessel, which is the left anterior descending artery, right coronary artery, or circumflex artery (or its branches), with stenosis degree ≥70% or ≥50% (Visually inspect ) and accompanied by evidence of ischemia; 4. The target lesion is a primary, in situ coronary artery lesion; 5. The reference vessel diameter for the target lesion is 2.0-4.0mm, and the length of the target lesion is ≤40mm (Visually inspect); 6. Visual assessment indicates that the lesion site can accommodate the passage of a pre-dilator or trial instrument through the lesion; 7. The target lesion site has moderate to severe calcification (meeting one of the following conditions): ① Angiography: Moderate calcification :clearer and more easily visible high-density shadows during cardiac pulsation; Severe calcification :clear high-density shadows both during and at rest; ② IVUS calcium score ≥2 points for superficial intimal, deep medial, and mixed calcification; 8. TIMI grade 3 in target vessel before registration (pre-dilation is allowed); Key exclusion Criteria: 1. Left ventricular ejection fraction \< 40%; 2. NYHA class III or IV heart failure; 3. Patients with single coronary artery supply; 4. Patients with evidence of dissection at the site of the lesion on imaging; 5. The imaging suggests that the vascular pathway is tortuous, making it difficult for the pre-dilatation device to reach the target location or to be retrieved; 6. Patients with active systemic infections; 7. Patients with uncontrollable severe hypertension (systolic pressure \> 180 mmHg or diastolic pressure \> 110 mmHg); 8. Patients with coagulopathy, hypercoagulable state or significant bleeding tendency (hemoglobin \<10g/dL or platelet count \<80×10\^9/L);
💊

What it tests

  • Shockplus-10
📍

Where

1 site
Beijing Anzhen Hosipital
Beijing, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy